Cordycepin protected against the TNF-α-induced inhibition of osteogenic differentiation of human adipose-derived mesenchymal stem cells. (September 2015)

• Record Type: Journal Article
• Authors: Yang, Jianping; Cao, Yan; Lv, Zhengxiang; Jiang, Tao; Wang, Liming; Li, Zhong
• Is Part Of: International journal of immunopathology and pharmacology. Volume 28:Number 3(2015)
• Page Start: 296
• Page End: 307
• Publication Date: 2015-09
• Subjects: adipose-derived mesenchymal stem cells -- bone diseases -- cordycepin -- inflammation; Immunopathology -- Periodicals; Pharmacology -- Periodicals; Inflammation -- Periodicals; 615.1
• DOI: 10.1177/0394632015592160
• Languages: English
• ISSNs: 0394-6320

Abstract

Cordycepin, 3'-deoxyadenosine, is an effective component isolated from the rare Chinese caterpillar fungus Cordyceps militaris . It exerts potent anti-inflammatory actions in different cell and animal models. However, its action remains unclear on the TNF-α-induced inhibition of osteogenic differentiation of adipose-derived mesenchymal stem cells (ADMSCs). In the present study, we demonstrated that cordycepin induced cell death at 20 and 40 μg/mL. Interestingly, 10 μg/mL cordycepin abrogated the cell death induced by 20 ng/mL TNF-α. Meanwhile, cordycepin exhibited a dose-dependent regulation of the osteogenesis of human ADMSCs: it promoted the differentiation at 10 μg/mL, whereas inhibited differentiation at 40 μg/mL. Furthermore, we discovered that 10 μg/mL cordycepin protected against the TNF-α (induced inhibition of osteogenic differentiation of human ADMSCs. It was also revealed that 10 μg/mL cordycepin restored Runx2 and Osx mRNA levels, which were significantly inhibited by TNF-αduring osteogenesis. At the same time, we found that 10 μg/mL cordycepin suppressed TNF-α-activated NF-κB signaling, by inhibiting IκBα phosphorylation and subsequent p65 release and translocation into the cell nucleus. Of clinical interest, the present study revealed mechanisms involved in inflammatory cytokine-inhibited osteogenesis, and it highlights the potential of cordycepin to promote the osteogenesis of human ADMSCs in cell-based therapy for inflammatory bone diseases.